Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/7912
Full metadata record
DC FieldValue
dc.contributor.authorAndrade, Sonia Gumes
dc.contributor.authorSilva, R. C.
dc.contributor.authorSantiago, Christiane Maria Gaspar
dc.contributor.authorFreitas, Luiz Antonio Rodrigues de
dc.date.accessioned2014-07-10T18:15:19Z
dc.date.available2014-07-10T18:15:19Z
dc.date.issued1987
dc.identifier.citationANDRADE, S. G. et al. Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study. Bulletin of the World Health Organization, v. 65, n. 5, p. 625-633, 1987.
dc.identifier.issn0042-9686
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/7912
dc.language.isoeng
dc.publisherWorld Health Organization
dc.rightsopen access
dc.titleTherapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study
dc.typeArticle
dc.description.abstractenThe anti-protozoal drug MK-436 (3-(J-methyl-5-nitroimidazol-2-yl)-3a,4,5,6,7,7ahexahydro-1,2-benzisoxazole) was found to be effective against Trypanosoma cruzi infections in mice (2 daily doses of250 mg per kg body weight). Parasitaemia disappeared within 24 hours oftreatment which was commenced during the early or late stages ofacute infection. Intracellular T. cruzi parasites were also affected by the drug, ultrastructural findings showing severe cytoplasmic vacuolization and membrane alterations. Positive serological responses persisted in the majority oftreated and parasitologically cured mice in the study. Cure rates varied from 72% to 100% and were similar regardless of the T. cruzi strain used (Y strain, type 1; 12 SF strain, type II; or Colombian strain, type III). However, the proportion ofpositive serological tests and the frequency of inflammatory lesions were greatestfor mice that were infected with the Colombian strain ofthe parasite.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
dc.creator.affilliationUniversidade Federal da Bahia. Salvador, BA, Brasil.
dc.creator.affilliationUniversidade Federal da Bahia. Salvador, BA, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil.
dc.subject.decsDoença de Chagas/quimioterapia
dc.subject.decsModelos Animais de Doenças
dc.subject.decsNitroimidazóis/uso terapêutico
dc.subject.decsTripanossomicidas/uso terapêutico
dc.subject.decsAnimais
dc.subject.decsCardiomiopatia Chagásica/parasitologia
dc.subject.decsCardiomiopatia Chagásica/patologia
dc.subject.decsDoença de Chagas/parasitologia
dc.subject.decsDoença de Chagas/patologia
dc.subject.decsFeminino
dc.subject.decsMasculino
dc.subject.decsCamundongos
dc.subject.decsMiocárdio/ultraestrutura
dc.subject.decsTripanossomicidas/farmacologia
dc.subject.decsTrypanosoma cruzi/efeitos de drogas
dc.subject.decsTrypanosoma cruzi/ultraestrutura
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Andrade SG Therapeutic action....pdf1.37 MBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.